Cargando…

Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival

BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has an extremely poor prognosis and there is currently no effective treatment for this condition. Direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) improves oxygenation, but it is unclear whether treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Enomoto, Noriyuki, Mikamo, Masashi, Oyama, Yoshiyuki, Kono, Masato, Hashimoto, Dai, Fujisawa, Tomoyuki, Inui, Naoki, Nakamura, Yutaro, Yasuda, Hideo, Kato, Akihiko, Mimuro, Soichiro, Doi, Matsuyuki, Sato, Shigehito, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349669/
https://www.ncbi.nlm.nih.gov/pubmed/25887940
http://dx.doi.org/10.1186/s12890-015-0004-4
_version_ 1782360060858466304
author Enomoto, Noriyuki
Mikamo, Masashi
Oyama, Yoshiyuki
Kono, Masato
Hashimoto, Dai
Fujisawa, Tomoyuki
Inui, Naoki
Nakamura, Yutaro
Yasuda, Hideo
Kato, Akihiko
Mimuro, Soichiro
Doi, Matsuyuki
Sato, Shigehito
Suda, Takafumi
author_facet Enomoto, Noriyuki
Mikamo, Masashi
Oyama, Yoshiyuki
Kono, Masato
Hashimoto, Dai
Fujisawa, Tomoyuki
Inui, Naoki
Nakamura, Yutaro
Yasuda, Hideo
Kato, Akihiko
Mimuro, Soichiro
Doi, Matsuyuki
Sato, Shigehito
Suda, Takafumi
author_sort Enomoto, Noriyuki
collection PubMed
description BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has an extremely poor prognosis and there is currently no effective treatment for this condition. Direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) improves oxygenation, but it is unclear whether treatment of AE-IPF with PMX-DHP affects survival. This study elucidated the effectiveness and safety of PMX-DHP for the treatment of AE-IPF. METHODS: This study included 31 patients with 41 episodes of AE-IPF. All patients received steroids. Of 31, 14 patients (20 episodes) were treated with PMX-DHP. The laboratory and physiological test results after the start of therapy and survival were retrospectively compared between patients treated with and without PMX-DHP. RESULTS: Patients treated with PMX-DHP had a significantly greater change in PaO(2)/FiO(2) ratio (mean ± SEM, 58.2 ± 22.5 vs. 0.7 ± 13.3, p = 0.034) and a smaller change in white blood cell count (−630 ± 959 /μL vs. 4500 ± 1190 /μL, p = 0.002) after 2 days of treatment than patients treated without PMX-DHP. The 12-month survival rate was significantly higher in patients treated with PMX-DHP (48.2% vs. 5.9%, p = 0.041). PMX-DHP was effective in patients with more severe underlying disease (GAP stages II or III; 12-month survival rate 57.1% with PMX-DHP vs. 0% without PMX-DHP, p = 0.021). Treatment with PMX-DHP was an independent predictor of better prognosis (hazard ratio 0.345, p = 0.037). Mild pulmonary thromboembolism occurred in one patient treated with PMX-DHP. CONCLUSIONS: Treatment of AE-IPF with PMX-DHP is tolerable and improves 12-month survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-015-0004-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4349669
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43496692015-03-05 Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival Enomoto, Noriyuki Mikamo, Masashi Oyama, Yoshiyuki Kono, Masato Hashimoto, Dai Fujisawa, Tomoyuki Inui, Naoki Nakamura, Yutaro Yasuda, Hideo Kato, Akihiko Mimuro, Soichiro Doi, Matsuyuki Sato, Shigehito Suda, Takafumi BMC Pulm Med Research Article BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has an extremely poor prognosis and there is currently no effective treatment for this condition. Direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) improves oxygenation, but it is unclear whether treatment of AE-IPF with PMX-DHP affects survival. This study elucidated the effectiveness and safety of PMX-DHP for the treatment of AE-IPF. METHODS: This study included 31 patients with 41 episodes of AE-IPF. All patients received steroids. Of 31, 14 patients (20 episodes) were treated with PMX-DHP. The laboratory and physiological test results after the start of therapy and survival were retrospectively compared between patients treated with and without PMX-DHP. RESULTS: Patients treated with PMX-DHP had a significantly greater change in PaO(2)/FiO(2) ratio (mean ± SEM, 58.2 ± 22.5 vs. 0.7 ± 13.3, p = 0.034) and a smaller change in white blood cell count (−630 ± 959 /μL vs. 4500 ± 1190 /μL, p = 0.002) after 2 days of treatment than patients treated without PMX-DHP. The 12-month survival rate was significantly higher in patients treated with PMX-DHP (48.2% vs. 5.9%, p = 0.041). PMX-DHP was effective in patients with more severe underlying disease (GAP stages II or III; 12-month survival rate 57.1% with PMX-DHP vs. 0% without PMX-DHP, p = 0.021). Treatment with PMX-DHP was an independent predictor of better prognosis (hazard ratio 0.345, p = 0.037). Mild pulmonary thromboembolism occurred in one patient treated with PMX-DHP. CONCLUSIONS: Treatment of AE-IPF with PMX-DHP is tolerable and improves 12-month survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12890-015-0004-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-22 /pmc/articles/PMC4349669/ /pubmed/25887940 http://dx.doi.org/10.1186/s12890-015-0004-4 Text en © Enomoto et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Enomoto, Noriyuki
Mikamo, Masashi
Oyama, Yoshiyuki
Kono, Masato
Hashimoto, Dai
Fujisawa, Tomoyuki
Inui, Naoki
Nakamura, Yutaro
Yasuda, Hideo
Kato, Akihiko
Mimuro, Soichiro
Doi, Matsuyuki
Sato, Shigehito
Suda, Takafumi
Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title_full Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title_fullStr Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title_full_unstemmed Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title_short Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival
title_sort treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin b-immobilized fiber column improves survival
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349669/
https://www.ncbi.nlm.nih.gov/pubmed/25887940
http://dx.doi.org/10.1186/s12890-015-0004-4
work_keys_str_mv AT enomotonoriyuki treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT mikamomasashi treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT oyamayoshiyuki treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT konomasato treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT hashimotodai treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT fujisawatomoyuki treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT inuinaoki treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT nakamurayutaro treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT yasudahideo treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT katoakihiko treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT mimurosoichiro treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT doimatsuyuki treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT satoshigehito treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival
AT sudatakafumi treatmentofacuteexacerbationofidiopathicpulmonaryfibrosiswithdirecthemoperfusionusingapolymyxinbimmobilizedfibercolumnimprovessurvival